Navigation Links
Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
Date:6/2/2008

Phase 2 Study for NKTR-102 Will Target Newly-Identified K-Ras Mutated

Oncogene Population in Patients with Advanced Colorectal Cancer New Phase 2 Clinical Trials Will Evaluate NKTR-102 in Advanced Breast and

Ovarian Cancers

SAN CARLOS, Calif., June 2 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced an expanded Phase 2 development plan for NKTR-102 (PEG-irinotecan). The company will target newly-characterized colorectal cancer patients with K-Ras mutated gene status in its Phase 2 study in advanced colorectal cancer. In addition, NKTR-102 will be evaluated in Phase 2 trials in two new indications: platinum-refractory ovarian cancer and advanced breast cancer that is refractory to anthracycline and/or taxane-based therapies. These studies are expected to commence in the second half of 2008.

Recent data(2) presented at the 2008 American Society of Clinical Oncologists (ASCO) Annual Meeting shows colorectal cancer (CRC) patients with tumors that have K-Ras oncogene mutations (K-Ras mutant types) do not respond to EGFR-inhibitors, such as cetuximab. It is estimated that up to 45% of colorectal cancer cases have this mutated K-Ras gene. To target this newly- characterized K-Ras mutant patient population, Nektar will initiate a prospective study to evaluate the efficacy of NKTR-102 monotherapy in these patients. The primary endpoint of this randomized trial will be a clinically meaningful improvement in progression-free survival as compared to standard irinotecan monotherapy.

"With these recent clinical studies on K-Ras, there is no longer a clear standard of care for the second-line treatment of advanced colorectal cancer in patients with the K-Ras gene mut
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 Former NASA scientist ... last week where he discussed Theradome™, the first portable ... The FOX segment shows firsthand how, via laser technology, ... loss solution that will not require surgery or medication.  ... at the base of the hair follicle, which is ...
(Date:5/4/2015)... MUNDELEIN, Ill. , May 4, 2015 ... , with live video and product demonstrations at the ... Radiology imaging equipment such as Kodak and Fuji Cr,s, ... be auctioned at the first event. Various imaging equipment ... www.RadiologyAuction.com . After years of buying ...
(Date:5/4/2015)... , May 4, 2015  Oncobiologics, Inc., a ... antibody (mAb) biosimilars, has completed the construction of ... headquarters in Cranbury, New Jersey ... facility is designed to utilize multiple technologies ... commercial scale.  Through the use of the latest ...
Breaking Medicine Technology:FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2RadiologyAuction Announces Event Starting On May 5th 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3
... The U.S. Food and Drug Administration today is ... because the highest approved dose--80 milligram (mg)--has been associated ... particularly during the first 12 months of use. ... agency is recommending that simvastatin 80 mg be used ...
... Neurologix, Inc. (OTCBB: NRGX) announced today several new results ... its novel, investigational gene therapy NLX-P101 for the treatment ... presentation of study findings to the National Institutes of ... analysis of new data showed patients treated with NLX-P101 ...
Cached Medicine Technology:FDA Announces New Safety Recommendations for High-Dose Simvastatin 2FDA Announces New Safety Recommendations for High-Dose Simvastatin 3Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 2Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 3Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 4Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 5Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 6Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 7Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 8Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 9
(Date:5/4/2015)... Each year, the Susan G. Komen organization hosts ... for breast cancer. This year, Dr. Mark Deutsch and his ... entertainment sponsor for the 25th annual Susan G. Komen Greater ... Lenox Square Mall. , The Komen organization hopes have 10,000 ... million. Perimeter Plastic Surgery has not only taken on the ...
(Date:5/4/2015)... Johnson & Wales University (JWU) held a ... academic center on Wednesday, April 22. , Johnson & Wales ... available by the re-alignment of Interstate-195. JWU’s new academic building, ... Chestnut streets in Providence, is scheduled to be completed in ... land the university purchased in 2012. , “It has long ...
(Date:5/4/2015)... West Orange, NJ (PRWEB) May 04, 2015 ... largest non-profit organization devoted exclusively to funding innovative lymphoma ... series of education programs, outreach initiatives and patient services ... Luncheon at the historic Mayfair Farms in West Orange, ... has raised nearly $500,000 for innovative research programs through ...
(Date:5/4/2015)... May 04, 2015 Baptist Medical ... Stroke Association’s Get With The Guidelines®-Stroke Gold Plus ... Honor Roll. The award recognizes the hospital’s commitment ... the most appropriate treatment according to nationally recognized, ... , To receive the Gold Plus Quality Achievement ...
(Date:5/4/2015)... CA (PRWEB) May 04, 2015 The ... as baby boomers join the ranks of senior citizens ... demand on an already over-burdened healthcare system. Additionally, as ... staff to replace them. Per the U.S. Census Bureau, ... expected to increase 75% by 2050 while those 25 ...
Breaking Medicine News(10 mins):Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4
... Healthcare, Inc., a leader in the field of kidney disease services ... Coplon Extramural Grants. Recipients of these annual grants are young scientists ... Canada who are pursuing innovative kidney disease research projects. ... ...
... MONDAY, Sept. 22 (HealthDay News) -- A new study ... have an underactive thyroid gland that does not cause ... As many as 27 million Americans have some type ... Clinical Endocrinologists; about half of these people are undiagnosed. ...
... new, previously unknown mechanism of immunity suggests that there ... and adults against Streptococcus pneumoniae (pneumococcal) infection, say researchers ... Health (HSPH). The findings, published in the open-access journal ... the development of novel pneumococcal vaccines. (The current vaccine, ...
... portion of sales of popular pink, suitcase ... MIAMI BEACH, Fla., Sept. 22 Nonprofit Charity ... up to provide,support for women diagnosed with breast cancer ... Cancer Awareness Month., Through the ,Dash for a ...
... Medical Policy Will Discuss New Paradigm for Health Plan ... ... WellPoint, Inc., the nation,s,largest health benefits company, today announced Dr. Alan ... Dr. Rosenberg, vice president of Medical Policy,Technology Assessment and Credentialing Programs ...
... of well-being, even death , , MONDAY, Sept. 22 (HealthDay ... comes to opportunities to empathize with the plight of ... While doctors are able to address such concerns as ... skirt "existential" issues, such as questions dealing with life ...
Cached Medicine News:Health News: Satellite Healthcare Announces 2008 Norman S. Coplon Extramural Grants : Grants Foster Next-Generation Kidney Disease Researchers 2Health News: Satellite Healthcare Announces 2008 Norman S. Coplon Extramural Grants : Grants Foster Next-Generation Kidney Disease Researchers 3Health News:Low Thyroid Function Linked to Heart Failure Risk 2Health News:Low Thyroid Function Linked to Heart Failure Risk 3Health News:New insights could lead to a better pneumococcal vaccine 2Health News:Nonprofit Charity for Women and Brookstone Dash to Fund Breast Cancer Support 2Health News:WellPoint's Dr. Alan Rosenberg to Address Industry's Top Medical Technology Conference 2Health News:WellPoint's Dr. Alan Rosenberg to Address Industry's Top Medical Technology Conference 3Health News:For Some Doctors, Empathy Is in Short Supply 2Health News:For Some Doctors, Empathy Is in Short Supply 3
Reliavac® 400cc kits with siliconized PVC drain, Y-connector tube...
Reliavac® 100cc low suction evacuator kits with flat drains and Y-connector tubing...
Reliavac 100cc evacuators offer a more constant suction profile than silicone evacuators. 100cc capacity is easy for patient to carry. Bottom emptying port reduces chance of contamination....
Used in the peritoneal cavity to remove large volumes of thick exudate....
Medicine Products: